Abstract: Provided is a method for preparing an epoxy substrate having a nanopattern, including: (a) forming a titanium oxide film by anodizing a titanium substrate; (b) obtaining a titanium substrate having a concave shape formed on the surface by removing the titanium oxide film from the titanium substrate on which the titanium oxide film has been formed; (c) coating an epoxy resin onto the titanium substrate on which the concave shape has been formed; and (d) obtaining an epoxy substrate having a nanopattern of convex surfaces by removing the titanium substrate.

Abstract: The present invention relates to a batroxobin-encoding nucleotide sequence and/or a mutated ?-factor secretion signal sequence, and a vector and a transformant using the same. The batroxobin-encoding nucleotide sequence of this invention exhibits an excellent expression efficiency in yeast, particular Pichia pastoris and the recombinant batroxobin is obtained at 4-13 fold higher yield than natural-occurring batroxobin-encoding sequences. The protein expression system which uses the batroxobin-encoding nucleotide sequence as well as mutated ?-factor secretion signal peptide sequence of this invention obtains the recombinant batroxobin at about 20-fold higher yield than natural-occurring batroxobin-encoding sequences. In addition, the recombinant batroxobin prepared using the sequence of this invention has a significantly plausible activity and stability compared with natural-occurring batroxobin.

Abstract: The present invention relates to a method for treating or reducing the development of a hyperproliferative disorder, which comprises administering to a subject a composition, which comprises as an active ingredient the compound represented by the Formula 1: wherein R1, R2, R3, R4, R5, R6 and R7 independently represent hydrogen, halo, hydroxyl, cyano, amino, nitro, nitroso, carboxyl, C1-C12 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, C1-C6 alkylamino, C1-C6 alkoxy, aryl, heteroaryl, arylalkyl, arylalkenyl or alkylaryl; X and Y independently represent hydrogen, oxygen, or sulfur, bound to a carbon atom via a single or double bond; Z represents hydrogen, halo, hydroxyl, cyano, amino, nitro, nitroso, carboxyl, C1-C12 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, C1-C6 alkylamino, C1-C6 alkoxy, aryl, heteroaryl, arylalkyl, arylalkenyl, alkylaryl or —NH—R8; R8 represents hydrogen, halo, hydroxyl, cyano, amino, nitro, nitroso, carboxyl, C1-C12 alkyl, C2-C6 alkenyl, C3-C8 cy

Abstract: The present invention relates to a batroxobin-encoding nucleotide sequence and/or a mutated ?-factor secretion signal sequence, and a vector and a transformant using the same. The batroxobin-encoding nucleotide sequence of this invention exhibits an excellent expression efficiency in yeast, particular Pichia pastoris and the recombinant batroxobin is obtained at 4-13 fold higher yield than natural-occurring batroxobin-encoding sequences. The protein expression system which uses the batroxobin-encoding nucleotide sequence as well as mutated ?-factor secretion signal peptide sequence of this invention obtains the recombinant batroxobin at about 20-fold higher yield than natural-occurring batroxobin-encoding sequences. In addition, the recombinant batroxobin prepared using the sequence of this invention has a significantly plausible activity and stability compared with natural-occurring batroxobin.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating hyperproliferative vascular disorders, and a pharmaceutical anticancer composition comprising the compound represented by the Formula 1. The present compounds exhibit IC50 values of less than 0.16 ?M for vascular smooth muscle cells and cancer cells to effectively prevent proliferation of vascular smooth muscle cells and cancer cells, thereby ensuring prevention or treatment of hyperproliferative vascular disorders such as arteriosclerosis and restenosis, and cancers.

Abstract: A recombinant thrombin-like enzyme batroxobin expressed by yeast, a production method thereof, and use of the batroxobin as a hemostatic agent or antithrombotic agent is disclosed. In order to express recombinant thrombin-like enzyme, an expression vector is prepared by inserting cDNA encoding the enzyme, the transformed cell is prepared by introducing the expression vector into the cell, the transformed cell then is incubated and the recombinant thrombin-like enzyme is obtained from the cell. The recombinant thrombin-like enzyme may be usefully used as a hemostatic agent because the enzyme effectively decrease bleeding time and blood coagulation time and does not affect various blood coagulation factors.